NAS:UTHR (USA) Also Trade In: Germany

United Therapeutics Corp $ 105.69 -0.98 (-0.92%)

Volume:
595,813
Avg Vol (1m):
282,827
Market Cap $:
4.69 Bil
Enterprise Value $:
3.93 Bil
P/E (TTM):
10.84
P/B:
1.52
Warning! GuruFocus has detected 2 Severe warning signs with UTHR. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for UTHR (United Therapeutics Corp) from 1999 to Sep 18 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. United Therapeutics stock (UTHR) PE ratio as of Sep 18 2020 is 10.84. More Details

United Therapeutics PE Ratio (TTM) Chart

EMBED

United Therapeutics PE Ratio (TTM) Historical Data

Total 1295
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
United Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-09-1810.9 2020-07-1712.0
2020-09-1711.0 2020-07-1611.9
2020-09-1610.9 2020-07-1512.4
2020-09-1510.9 2020-07-1412.2
2020-09-1410.8 2020-07-1311.9
2020-09-1110.5 2020-07-1012.1
2020-09-1010.5 2020-07-0912.0
2020-09-0910.7 2020-07-0812.1
2020-09-0810.6 2020-07-0712.2
2020-09-0710.8 2020-07-0612.2
2020-09-0410.8 2020-07-0312.4
2020-09-0310.7 2020-07-0212.4
2020-09-0211.2 2020-07-0112.4
2020-09-0110.8 2020-06-3012.4
2020-08-3111.0 2020-06-2912.3
2020-08-2810.9 2020-06-2610.0
2020-08-2710.9 2020-06-2510.4
2020-08-2610.8 2020-06-2410.1
2020-08-2510.8 2020-06-2310.1
2020-08-2410.9 2020-06-229.9
2020-08-2111.0 2020-06-199.9
2020-08-2011.0 2020-06-189.7
2020-08-1911.0 2020-06-179.8
2020-08-1811.4 2020-06-169.5
2020-08-1711.4 2020-06-159.5
2020-08-1411.2 2020-06-129.6
2020-08-1311.2 2020-06-119.7
2020-08-1211.4 2020-06-1010.3
2020-08-1111.2 2020-06-0910.4
2020-08-1011.4 2020-06-0810.5
2020-08-0711.6 2020-06-0510.3
2020-08-0611.5 2020-06-0410.2
2020-08-0511.6 2020-06-0310.5
2020-08-0411.7 2020-06-0210.3
2020-08-0312.0 2020-06-0110.0
2020-07-3111.4 2020-05-299.8
2020-07-3011.7 2020-05-289.6
2020-07-2911.6 2020-05-279.7
2020-07-2811.6 2020-05-269.9
2020-07-2711.8 2020-05-259.8
2020-07-2411.5 2020-05-229.8
2020-07-2311.8 2020-05-219.8
2020-07-2211.7 2020-05-2010.0
2020-07-2111.6 2020-05-199.9
2020-07-2011.8 2020-05-1810.0

United Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries UTH.Germany UTHR.USA
Address 1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for pulmonary arterial hypertension largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug, but its focus largely remains in pulmonary hypertension.